The novel GLP ‐1‐gastrin dual agonist, ZP3022 , increases β‐cell mass and prevents diabetes in db/db mice

Key Points

• To assess the effects of the novel GLP-1-gastrin dual agonist ZP3022 on glycaemic control, islet mass, and β-cell mass in diabetic db/db mice.
• Treated diabetic db/db mouse models with either the novel dual agonist ZP3022 or a vehicle control.
• Evaluated glycaemic parameters alongside quantitative changes in pancreatic islet and β-cell mass.
• Pancreatic islet and β-cell mass increased significantly following ZP3022 administration compared with vehicle.
• ZP3022 treatment resulted in improved glycaemic control and prevented diabetes progression in db/db mice.